Abstract. Connective tissue growth factor (CTGF) is now considered to be one of the important driver molecules for the pathogenesis of diabetic nephropathy (DN) and possibly many other fibrotic disorders. However, the molecular mechanisms by which CTGF functions remain to be established. In an attempt to define these mechanisms, this study was designed to investigate whether CTGF has any effect on the cell cycle of human mesangial cells (HMC), which are known to undergo hypertrophy in DN. This report provides the first evidence that CTGF is a hypertrophic factor for HMC. CTGF stimulates HMC to actively enter the G 1 phase from G 0 , but they do not then progress further through the cell cycle. The molecular mechanisms underlying this G 1 phase arrest appear to be due to the induction of the cyclin-dependent kinase inhibitors (CDKI) p15 INK4
, p21 Cip1 , and p27 Kip1 , which are known to bind and inactivate cyclinD/CDK4/6 and the cyclin E/CDK2 kinase complexes. This could account for the maintenance of pRb protein in a non-or very low-phosphorylated state, preventing cell cycle progression. Using CTGF antisense oligonucleotides, the results also indicate that the previously identified transforming growth factor-␤ (TGF-␤)-induced hypertrophy in mesangial cells is CTGF-dependent. Mesangial cell hypertrophy is one of the earliest abnormalities of diabetic nephropathy; therefore, therapeutic strategies targeting CTGF may be beneficial in controlling DN.
Diabetic Nephropathy (DN) is associated with mesangial cell hypertrophy rather than with cell proliferation (1, 2) . Cellular hypertrophy is characterized by a halt in the cell cycle at the G 1 phase, with the continued production of cellular proteins, which subsequently leads to an increase in the overall size of the cell (3) . Previously, cell cycle analysis revealed that prolonged exposure to high concentrations of glucose arrests mesangial cells in the G 1 phase with the concomitant induction of hypertrophy. The effect was found to be mediated by the autocrine synthesis and activation of transforming growth factor-␤ (TGF-␤) (4, 5) . Elevated expression levels of cyclindependent kinase inhibitors (CDKI), such as p15, p16, p21, and p27 (6 -13) , are the main cause of this cell cycle arrest at G 1 . Glomerular hypertrophy in DN could be considered an early marker for the development of irreversible glomerulosclerosis (3, 14, 15) . Therefore, it is important to understand the pathways leading to mesangial cell growth arrest and hypertrophy. We hypothesized that connective tissue growth factor (CTGF) (CCN2), an immediate early gene encoding a 38-kD cysteinerich protein and a member of the CCN family of cytokines, may act downstream of TGF-␤ to mediate mesangial cell hypertrophy.
CTGF appears to be involved in diverse autocrine or paracrine actions in many different cell types (16) . It has been reported to have mitogenic activity (17) and to mediate cell adhesion (18) , angiogenesis (19) , increased cell migration (20, 21) and cell survival (22) , induction of apoptosis (23) , and regulation of gene expression (17,24 -27) . Its expression in mesangial cells is induced by exposure to high glucose or to TGF-␤, and it mediates some of the biologic effects of the latter (27) .
There is strong evidence that CTGF plays a key role in the pathogenesis of many fibrotic disorders, including DN (25) (26) (27) (28) . However, the molecular mechanisms by which CTGF exerts these effects remain to be established. In an attempt to define these mechanisms, we investigated whether CTGF plays a role in mesangial cell hypertrophy.
Materials and Methods

Cell Cultures, Antibodies, and Reagents
Primary normal adult human mesangial cells (CC-2259, lot 3F1510) were purchased from Biowhittaker (Wokingham, Berkshire, UK) and maintained in culture as described previously (29) and used at passage 9 to 10. Antibodies against Phospho-Rb (Ser 780) and Phospho-Rb (Ser 795), Phospho-Rb (Ser-807/Ser811), Phospho-p53 (Ser 15) 16G8, Phospho-MAPK (Erk1/2) (Thr202/Tyr204), p44/42 MAP kinase were from New England Biolabs (Hitchin, Hertfordshire, UK). The p21 and Rb antibodies were from TCS Biosciences Ltd (Buckingham, UK). Antibodies against p27 (C19) and cyclin D1 (R124) were from Santa Cruz (Santa Cruz, CA). The antibody against p15 was from Serotec (Kidlington, Oxford, UK). rCTGF was ex-pressed in transformed HMC and purified from the medium using Talon metal affinity resin, as reported previously (27) . TGF-␤ was purchased from R & D Systems (Abingdon, Oxfordshire, UK). Phosphothioate antisense (TGG GCA GAC GAA CG) and control oligonucleotides (ACC GAC CGA CGT GT) directed to CTGF were designed and manufactured by Biognostik GmbH (Göttingen, Germany), who own the intellectual property rights to the sequences (27) .
Cell Cycle Analysis by Fluorescence-Activated Cell Sorter (FACS)
Cells were trypsinized, washed, collected, and fixed with 70% ethanol for 24 h after treatments. Fixed samples were centrifuged, treated with 100 g/ml RNase A, and resuspended in 50 g/ml propidium iodide. Stained cells (20,000 events) were analyzed on a FACS flow cytometer (Becton Dickinson, Franklin Lakes, NJ). The percentage of cells within the G 1 /S and G 2 /M phases of the cell cycle were determined by analysis with the CellQuest software provided by Becton-Dickinson.
Determining the Hypertrophy Index
Cells were made quiescent for 2 d in serum-free medium containing 4 mM glucose. The cultures were then treated with growth factors for 24 h, after which the cells were trypsinized, washed twice with phosphate-buffered saline (PBS) and counted using an improved Neubauer hemocytometer. 
Western Blotting
Cells were lysed in reducing SDS-PAGE loading buffer and immediately scraped off the plate. Cell lysates were sonicated for 10 s to shear DNA. Samples were boiled for 5 min and resolved on 4 to 12% gradient gels by SDS-PAGE. Proteins were transferred onto a polyvinylidene difluoride membrane filter (Immobilin-P, Millipore, Bedford, UK) using a BioRad (Hercules, CA) transfer apparatus. Blots were incubated in blocking buffer containing 1ϫ Tris-buffered saline (TBS), 0.1% Tween-20 with 5% (wt/vol) nonfat dry milk for 1 h. Immunodetection was performed by incubating the blots in primary antibody at the appropriate dilution in antibody dilution buffer (1ϫ TBS, 0.1% Tween-20 with 5% bovine serum albumin [BSA]) overnight at 4°C. Blots were then washed three times with washing buffer (1ϫ TBS, 0.1% Tween-20) and incubated with secondary horseradish peroxidase (HRP)-conjugated antibodies for 1 h at room temperature. Bound antibodies were visualized using the enhanced chemiluminescence reagent Luminol (Autogen Bioclear UK Ltd, Wiltshire, UK). Prestained molecular weight standards (Amersham International PLC, Amersham, UK) were used to monitor protein migration.
Immunofluorescence Staining
Cells were fixed with 3.7% paraformaldehyde and permeabilized with 0.5% Triton X-100 in PBS for 10 min at room temperature. Coverslips were then incubated overnight at 4°C with serum (5% in PBS) from the same species as that in which the secondary antibody was raised. They were then incubated with primary antibodies (at optimum dilution in PBS containing 3% BSA) for 1 h at 37°C. Coverslips were then washed and incubated in the dark for 1 h with fluorescein-conjugated secondary antibody (Sigma Aldrich, Dorset, U.K.). After staining, the coverslips were mounted on glass slides with anti-fade mounting media (Vector Labs, Peterborough, UK) and examined using a fluorescence microscope.
Use of Antisense-CTGF Oligonucleotides
A CTGF mRNA antisense oligonucleotide (2 M, as recommended by the manufacturer) or a CG-matched randomized sequence oligonucleotide (negative control) was added directly to cultures.
Transient Transfection and Reporter Gene Assay
p21 promoter-luciferase reporter gene constructs (30) or the pGL-3 basic vector were transfected by electroporation at a concentration of 15 g with 5 g of the pSV-␤-Galactosidase Control Vector (Promega, Southampton, UK) into 25 ϫ 10 6 transformed human mesangial cells (THMC) using conditions described previously (27) . Fortyeight hours after transfection, cells were lysed in the reporter lysis buffer (RLB), which permits both luciferase and ␤-galactosidase assays, using Promega Kits. Luciferase activity was normalized to ␤-galactosidase activity to correct for any difference in transfection efficiency.
Results
Effect of CTGF on Cell Cycle Distribution in HMC
To investigate whether CTGF has an effect on the cell cycle of HMC, cells were seeded in dishes in equal numbers and left to grow to 50 to 60% confluence in medium containing 10% fetal calf serum (FCS). Cells were then washed twice with PBS buffer and maintained in medium containing 0.2% FCS. After 48 h, the growth-arrested cells were washed and incubated in serum-free medium for 2 h before adding CTGF (80 ng/ml), TGF-␤ (5 ng/ml), or FCS (10%), after which they were incubated for an additional 24 h. The cell cycle distribution of the HMC was then analyzed by FACS after staining DNA with propidium iodide. Figure 1A demonstrates that after growth arrest by serum deprivation, an average of 91% of HMC was arrested in the G 0 /G 1 phase, 2% in the S phase, and 7% in G 2 /M phase. Treatment with CTGF for 24 h ( Figure 1B ) did not alter the cycle distribution (91% of cells was arrested in G 0 /G 1 phase, 3% in S phase, and 6% in G 2 /M phase), indicating that, in contrast to some other cell types, it is not a mitogen for HMC. This result is very similar to that in Figure 1C , which was obtained when HMC were treated with 5 ng/ml TGF-␤ (91% of cells was arrested in G 0 /G 1 phase, 3% in S phase, and 6% in G 2 /M phase). TGF-␤ has been shown by others to inhibit MC DNA synthesis in response to mitogens (31) . In contrast, after 10% serum stimulation for 24 h, the percentage of cells in G 0 /G 1 phase decreased to 58%, whereas 12% were in S phase and 30% in G 2 /M phase, confirming HMC responsiveness to mitogens There was no apparent change in the cell number after 24 and 48 h of treatment with CTGF. However, when the CTGFtreated cells were washed with PBS and then incubated in medium containing 10% FCS, they reverted to the proliferative phenotype, reaching confluence within 3 d. Thus the cells were not irreversibly arrested or senescent after treatment with CTGF.
CTGF Induces Cellular Hypertrophy of HMC
To investigate whether the G 0 /G 1 phase-arrested HMC undergo cellular hypertrophy in response to CTGF, we determined the hypertrophy index (ratio of total protein content to cell number) after 24-h incubation (5) . As shown in Figure 2 , 80 ng/ml CTGF induced cellular hypertrophy of HMC by 30%. TGF-␤ (5 ng/ml) induced cellular hypertrophy by 42%, which is in agreement with the findings of Wolf et al. (5) . Interestingly, treatment with CTGF antisense oligonucleotide (2 M) completely abolished TGF-␤-dependent hypertrophy, whereas the control CTGF antisense oligonucleotide (2 M) had no effect. We have shown previously that the markedly increased CTGF mRNA pool in either TGF-␤-or high glucose-stimulated HMC is reduced to below basal levels when cultures are treated with CTGF antisense oligonucleotide and that changes in CTGF mRNA levels correlate closely with changes in CTGF protein levels (27) .
CTGF Regulates Protein Expression of the G 1 Phase Cyclins and CDKI in HMC
To understand the molecular mechanisms underlying CTGF-mediated hypertrophy, we carried out experiments in which serum-starved cells were treated with the growth factor for different periods of time and then lysed. The cell lysates were used for Western blotting to assess the expression levels of several key regulatory G1 phase proteins. Figure 3 shows the results obtained for quiescent HMC that were stimulated with 80 ng/ml CTGF for periods up to 24 h. CTGF stimulated the cells to actively enter the cell cycle as is clearly indicated by the increased expression level of cyclin D protein within 30 min of the addition of CTGF ( Figure 3A) . The Western blot was quantified by densitometry. Cyclin D1 levels were increased by twofold and threefold after 30 min and 2 h, respectively, and remained elevated until 24 h. In contrast, cyclin E was hardly detectable at any time during the experiment (data not shown). CTGF also stimulated increased expression of the cell cycle negative regulators, the CDKI p15 INK4 , p21 Cip1 ,and p27
Kip1 (Figure 3 , B, C, and D, respectively). Mesangial cells were also synchronized by serum withdrawal for 24 h and then treated with 80 ng/ml rCTGF in the presence of 10% FCS for 24 h. The expression of CDKI was examined after 2 h and at 24 h. Under these conditions, there was no induction of p15 INK4 , but p27
Kip1 was increased at both 2 h and 24 h and p21
Cip1 at 24 h, though not so markedly as in quiescent cells (data not shown). Thus, even in the presence of a very strong unphysiologic mitogen such as 10% FCS, rCTGF is still able to induce key regulatory CDKI.
CTGF Does Not Stimulate Phosphorylation of Retinoblastoma Protein (pRb)
The phosphorylation status of the negative cell cycle regulator protein, pRb, can determine whether cells proliferate or hypertrophy in response to growth factors (31-33). Thus we examined whether changes in pRb protein phosphorylation occur on treatment of mesangial cells with CTGF. We used a Figure 2 . CTGF induces cellular hypertrophy of HMC. Growtharrested HMC were treated with CTGF, TGF-␤, TGF-␤ in the presence of CTGF antisense oligonucleotide, or control CTGF antisense for 24 h. The hypertrophy index was determined as described in the Materials and Methods section. The figure shows the results from three independent experiments, which were pooled and expressed as the mean Ϯ SEM. Triplicate or quadruplicate cultures were assessed for each condition in each experiment (total n ϭ 11). Statistical analyses were performed using a two-sample unpaired t test. *P Ͻ 0.001. (Figure 4) . The results indicate that in serumdeprived quiescent cells phosphorylated pRb is barely detectable. Neither the level of total pRb nor of phospho-pRb changed significantly over the experimental period after the addition of CTGF. In contrast, 10% FCS markedly induced pRb phosphorylation within 12 h of stimulation. Similar results were obtained when we used phospho-Rb (Ser780) and phospho-Rb (Ser795) antibodies (data not shown). This indicates that hyperphosphorylation of pRb, which is required for the S phase transition (32,34) does not occur after treatment of HMC with CTGF.
When mesangial cells were deprived of serum for 24 h and then treated simultaneously with 10% FCS and 80 ng/ml rCTGF, the latter was not able to suppress phosphorylation of pRb (data not shown). This finding is consistent with the observation that p15
INK4 was not induced under these conditions (see above), this CDK1 being an inhibitor of the cyclin D1/cdk4/6 complex, which hypophosphorylates pRb (see Discussion).
CTGF Induces MAP Kinase (ERK)
The classical MAP kinase (ERK) has been reported to be a critical mediator of the cell-cycle machinery, particularly at the G1 phase. Transcription of the cyclin D1 gene as well as the cyclin D1 protein level has been shown to be regulated by the MAPK cascade (35, 36) . Direct phosphorylation of the CDKI p27 Kip1 by MAP kinase increases the stability of the protein (37) . Activation of the ERK MAP kinase pathway has also been implicated with the increased transcription of p21 Cip1 (38, 39) . We therefore investigated whether CTGF activates the MAPK pathway. The results show that CTGF indeed activates the MAPK pathway in HMC within 5 min of exposure to the growth factor and that this activity is sustained for 24 h ( Figure  5A ). Activation and nuclear translocation of the MAP kinase was also confirmed by immunofluorescence ( Figure 5B ).
Modification and Stabilization of p53 by CTGF in HMC
The p53 protein is a stress-responsive transcription factor that is induced by a variety of stimuli, which act through mechanisms that stabilize the protein posttranscriptionally, including phosphorylation (40) . It can initiate cell cycle arrest at the G 1 /S transition or apoptosis. Induction of a G 1 /S block by p53 is due partly to its ability to transactivate the CDKI p21 Cip1 gene (41). Phosphorylation of p53 at Ser15 is critical for the activation of this protein (42, 43) , its stabilization and nuclear accumulation (44, 45) , and its interaction with the transcriptional coactivators CBP/p300 and PCAF (46) . Therefore, we examined the phosphorylation status of p53 at Ser15 in HMC after exposure of quiescent cells to CTGF for different periods of time. Figure 6A reveals that CTGF induces the phosphorylation of p53 at Ser15 with maximum induction after 2 h of exposure. This time appears to be similar to that required to bring about the maximum accumulation of p21 (Figure 3 ). Nuclear accumulation of phosphorylated p53 at Ser15 was also detected by immunofluorescence ( Figure 6B ). The presence of 10% FCS abolished the CTGF-induced phosphorylation of p53 (data not shown). However, serum supplemented cultures contained only very low levels of total p53 (data not shown), presumably because the nonphosphorylated protein is unstable and rapidly removed (40) .
To determine whether CTGF induces transcription of the p21
Cip1 gene in quiescent HMC in a p53-dependent manner, we used the murine p21 promoter-luciferase reporter gene. Constructs prepared by Xiao et al. (30) were used. The human, rat, and mouse p21 promoters all have two p53 binding site Figure 4 . CTGF does not stimulate phosphorylation of retinoblastoma protein (pRb). Growth-arrested HMC were treated with CTGF or 10% FCS. At the time points indicated, cell extracts were prepared and equal volumes were analyzed by Western blotting, as described in the Materials and Methods section using a specific anti-phospho-Rb (Ser 807/Ser 811) antibody. Expression of ␤-actin protein was examined as a quantity loading control. motifs (47) . The constructs used in this study consisted of the wild-type construct, which contains two p53 binding sites situated near nt-2800 and nt-1900 relative to the TATA box; mutant 1 where the p53 binding site near nt-2800 was mutated; and mutant 2 where the p53 binding site near nt-1900 was mutated. The relative activity of the p21 promoters in driving luciferase transcription in the absence or presence of 80 ng/ml CTGF was tested. Figure 7 summarizes the results of three independent experiments. As shown in the figure, CTGF led to a twofold enhancement of basal activity of the wild-type promoter. Mutating the first p53 binding site near nt-2800 resulted in a 60% reduction of the basal activity of the wild-type p21 promoter. CTGF-enhanced activity was also abolished. In contrast, mutating the second p53 binding site near nt-1900 had no significant effect on either the basal activity of the promoter or on the enhanced activity induced by CTGF.
CTGF Mediates TGF-␤-Induced Expression of CDKI in HMC
Finally, we investigated whether CTGF mediates TGF-␤-dependent hypertrophy by regulating the expression of the CDKI of the G 1 phase. We carried out experiments in which cells were treated with 5 ng/ml TGF-␤ in the presence or absence of CTGF antisense or control antisense oligonucleotides (2 M). Cells were then lysed, and cell lysates were used for Western blotting to assess the expression levels of p15 INK4 , p21 Cip1 , and p27 Kip1 proteins. Figure 8 shows that TGF-␤ increased the expression level of all three CDKI after 24 h. This increased expression was abrogated in the presence of CTGF antisense oligonucleotide but not in the presence of control CTGF antisense oligonucleotide.
Discussion
CTGF is now considered to be an important driver molecule for the pathogenesis of DN, and our previous work showed its likely involvement as one of the pathways stimulating the deposition of extracellular matrix around mesangial cells exposed to high-glucose conditions (27) . Our major goal is to understand the molecular mechanisms through which this -3) , or p21 promoter-reporters in which the p53 binding sites had been deleted (mutant 1, mutant 2), were transiently cotransfected with the pSV-␤-galactosidase control vector into a mesangial cell line by electroporation, as described in the Materials and Methods section. The cultures were incubated in medium with (Ⅵ) or without (^) 80 ng/ml CTGF. Luciferase activity was assayed 48 h after transfection and 18 h after the addition of CTGF and was normalized to the ␤-galactosidase activity to correct for any difference in transfection efficiency. The results represent the mean Ϯ SEM of three independent experiments (three replicates for each experiment). Statistical analyses were used to compare samples incubated with or without CTGF. The analyses were performed using a two-sample unpaired t test. *P Ͻ 0.001. growth factor functions. This will undoubtedly help in designing specific drugs to control fibrosis in the diabetic kidney and possibly in many other fibrotic disorders. In the present study, we investigated whether CTGF has an effect on the HMC cell cycle, as cell cycle analysis can be informative as to whether growth factors have proliferative or hypertrophic effects on specific cell types.
When stimulated with growth factors, quiescent cells (G 0 ) enter the cell cycle (48, 49) at the G 1 phase, where they increase their size and exhibit enhanced RNA and protein synthesis. After passing a restriction point in late G 1 , they become committed to enter the S phase and are no longer responsive to growth factors. DNA replication occurs in the S phase. Cells then progress through G 2 and enter mitosis, where they divide. Cell proliferation requires normal progression through the cell cycle while cell hypertrophy occurs when the cell cycle is arrested in G 1 (50, 51) . In contrast, apoptosis occurs when cells exit from the cell cycle, typically in G 1 (52) .
The cell cycle is controlled by positive and negative regulators. The positive regulators are cyclin/cyclin-dependent kinase (CDK) complexes (53) (54) (55) (56) . Cell cycle entry in mammalian cells requires the synthesis of the D-type cyclins (D1-3) that associate with and activate CDK4/6 (54). This in turn hypophosphorylates pRb, the retinoblastoma protein, a key regulator of events in G 1 (see below). The negative regulators are CDK inhibitors (CDKI), which are grouped into two families (57) . The INK4 family (p15, p16, p18, p19, and p20) only bind to the cyclin D/CDK4/6 complex and inhibit its activity, whereas the CIP/KIP family (p21 Cip1 , p27 Kip1 , and p57 Kip2 ) bind to and inhibit cyclin-CDK complexes containing either CDK4/6 or CDK2. Our results show that CTGF induces cyclin D1 levels, but also simultaneously p15 INK4 , p21 Cip1 , and p27
Kip1 . p21 transcription was induced by CTGF via a phospho p53-dependent mechanism.
It seems likely that mesangial cells exposed to CTGF arrest in the early G 1 phase of the cell cycle. pRb exists in three different states of phosphorylation-a non-phosphorylated state, which is inactive and associated with G 0 cells, a hypophosphorylated state, which acts as a transcriptional repressor of E2F-regulated genes in early G 1 , and a hyperphosphorylated state which dissociates from E2F and allows transcription of genes required for late G 1 and S phase of the cell cycle (58, 59) . Hyperphosphorylation of pRb is driven by cyclinE-CDK2, which is activated during transition across the restriction point in the late G 1 phase (58) . Cyclin E was barely detected in CTGF-treated HMC, and there was no evidence for increased phosphorylation of pRb in these cells, whereas phosphorylation occurred in FCS-stimulated cells. Thus CTGF-treated HMC do not enter late G 1 phase. However, exposure to CTGF does lead to a rapid increase in cyclin D1 levels, indicating entry into the G 1 phase. This rapid increase is likely to be due to protein stabilization after phosphorylation by MAPK.
Cyclin D1/CDK4/6 complex is active throughout the G 1 phase, and one of its roles is to hypophosphorylate pRb in early G 1 (59) . However, we observed no measurable increase in phosphorylation of pRb in CTGF-treated cells compared with that in serum-deprived HMC. This may be due to the very early induction in CTGF-treated cells of p15 INK4 , a specific inhibitor of cyclin D activation (57) . It is noteworthy that protein transduction of the related p16 INK inhibitor of CDK4/6 into mitogen-stimulated lymphocytes completely blocked phosphorylation of pRb in early G 1 phase, whereas control cells contained hypophosphorylated pRb (59) . Thus our data are consistent with arrest in early G 1 phase when HMC are exposed to CTGF.
Cyclin D1 does not appear to be essential for the development of most tissues, as demonstrated by the phenotype of knockout mice (60) . However, it has been proposed that it has a role in promoting cell growth. Studies on Drosophila provide convincing evidence for this in that organism (61) , but it has also been proposed that renal epithelial cell hypertrophy depends on cyclin D kinase activation to stimulate protein synthesis as cells enter the cycle without subsequent cyclin E kinase activation (62) . The connecting pathways to protein synthesis are not understood, but if a similar mechanism is operative in bringing about hypertrophy of CTGF-arrested cells, it must involve some kinase activity that is subtly different from that responsible for hypophosphorylation of pRb which, as discussed above, appears to be inhibited.
Prolonged exposure to high glucose or to TGF-␤ have been found to arrest mesangial cells in the G 1 phase with concomitant cellular hypertrophy (3, 4, 63, 64) . Indeed, high glucoseinduced hypertrophy was found to be mediated by TGF-␤ because it could be prevented by neutralizing antibodies to the molecule (4). Treatment with TGF-␤-neutralizing antibodies was also shown to attenuate mesangial cell hypertrophy in diabetic mice (65) . Both in vivo and in vitro studies indicate that the molecular mechanisms underlying this G 1 -phase arrest involve the overexpression of p21 Cip1 and p27 Kip1 proteins and absence of phosphorylation of pRb (Table 1) . CTGF antisense, but not missense, oligonucleotides abolished TGF-␤-induced hypertrophy and abrogated TGF-␤-dependent expression of p15 INK4 , p21 Cip1 , and p27
Kip1 ; this suggests that TGF-␤-dependent G 1 phase arrest and induced hypertrophy is mediated through CTGF. Although CTGF has been reported to be pro- apoptotic for MC (66) we did not observe this in our experiments that used a concentration of 80 ng/ml. Moreover, it has been shown that induction of p27, a downstream effector of CTGF, limits apoptosis in mesangial cells and fibroblasts in vitro (67) .
Transient transfection experiments with a p21 promoterluciferase-reporter gene indicated that CTGF enhances the expression of p21 in THMC cells. This occurs in a p53-dependant manner via the first p53 binding site of the promoter. This site, unlike the second p53 binding site, has two copies of the consensus decamer motif 5'-RRRCWWGYYY-3', where R ϭ G or A, W ϭ T or A, and Y ϭ C or T (68) . In agreement with this result, CTGF also induces the phosphorylation of the transcription factor p53 at Ser15 and its nuclear accumulation in HMC. This mechanism may be also significant in mediating the regulation of other genes by CTGF such as TSP-1 (69), MMP-2 (70), and PAI-1 (27) , which have two or more p53 binding sites in their promoters (71) .
In summary, our results strongly indicate that CTGF is a hypertrophic factor for HMC. CTGF stimulates these cells to actively enter the G 1 phase from G 0 but not to progress further through the cell cycle. The molecular mechanisms underlying this G 1 phase arrest appear to be due to the induction of the CDKI, p15 INK4 , p21 Cip1 , and p27 Kip1 , which subsequently bind to and inactivate cyclinD/CDK4/6 and cyclin E/CDK2 kinase complexes. The inhibition of these G 1 -phase cyclin/CDK complexes results in very low or no phosphorylation of the pRb protein leading to cell cycle arrest. Finally, the results of experiments using CTGF antisense oligonucleotides indicate that CTGF functions as a downstream mediator of TGF-␤ hypertrophic activity in mesangial cells. Interestingly, CTGF has also been shown to function as a downstream mediator of TGF-␤ mitogenic activity in NRK fibroblasts in suspension cultures (72) by controlling cell cycle progression through the G 1 /S phase. Under these conditions, CTGF induces the level of cyclin A activity via the reduction of p27
Kip1 levels, which results in the hyperphosphorylation of pRb and release of E2F.
